Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.39 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | GRIK1 | P39086 | 8/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 8/20 | 0.38 |
| ▸ | CPA1 | P15085 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.35 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6402173 | 0.87 | GRIK1 (0.55) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL1845715 | 0.84 | — | — | |
| SCHEMBL3020454 | 0.84 | FOLH1 (0.50) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL12951777 | 0.80 | GRIK1 (0.35) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL9378420 | 0.80 | CHRM1 (0.65) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL526016 | 0.80 | SLC1A3 (0.52) | GRIK1GRIK2CPA1SLC1A1SLC1A3 | |
| SCHEMBL7137298 | 0.80 | CHRM1 (0.65) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL16062048 | 0.80 | CHRM1 (0.65) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL16649193 | 0.78 | GRIK1 (0.40) | CHRM1AKR1A1CHRM3HTR2AHTR2C | |
| SCHEMBL29636386 | 0.78 | CHRM1 (0.34) | CHRM1AKR1A1CHRM3HTR2AHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117500785-A | Azetidinyl-containing carboxylic acid compounds for the treatment of neurodegenerative diseases | 细胞基因公司 | 2024-02-02 | — | — | CN | disclosed |
| US-20230321261-A1 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2023-10-12 | — | — | US | disclosed |
| US-20180214549-A1 | ANTIBODIES BINDING AXL | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2018-08-02 | — | — | US | disclosed |
| US-9981046-B2 | Drug-conjugates, conjugation methods, and uses thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2018-05-29 | — | — | US | disclosed |
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | SORRENTO THERAPEUTICS, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-9801951-B2 | Drug-conjugates, conjugation methods, and uses thereof | CONCORTIS BIOSYSTEMS, CORP. (US) | 2017-10-31 | — | — | US | disclosed |
| US-20170157250-A1 | ANTIBODIES BINDING AXL | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-08 | — | — | US | disclosed |
| US-20170157250-A1 | ANTIBODIES BINDING AXL | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2017-06-08 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. (US) | 2016-03-10 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | Concortis Biosystems, Corp., a wholly owned subsidary of Sorrento Therapeutics, Inc, (US) | 2015-05-21 | — | — | US | disclosed |
| US-7608714-B2 | Production of dolasetron | TEVA Gyógyszergyár Zártkörúen Müködö Részvénytársaság (HU) | 2009-10-27 | — | — | US | disclosed |
| US-20070203219-A1 | Production of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
| US-20070203175-A1 | Productioin of dolasetron | TEVA PHARMACEUTICALS USA, INC. | 2007-08-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180085471-A1 | DRUG-CONJUGATES, CONJUGATION METHODS, AND USES THEREOF | ABCG2, UGT2B7, UGT1A9 | CHRM1 3647/4885AKR1A1 1703/4885CHRM3 2656/4885 |
| US-20160067350-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | PAICS, CES2, DNPEP | CHRM1 3152/4885AKR1A1 1542/4885CHRM3 2687/4885 |
| US-20150141646-A1 | Drug-Conjugates, Conjugation Methods, and Uses Thereof | ABCG2, UGT2B7, UGT1A9 | CHRM1 3647/4885AKR1A1 1703/4885CHRM3 2656/4885 |
| US-20180214549-A1 | ANTIBODIES BINDING AXL | AXL, CD47, TYRO3 | CHRM1 4117/4885AKR1A1 4604/4885CHRM3 3361/4885 |
| US-20070203175-A1 | Productioin of dolasetron | DDOST, ALG8, DUT | CHRM1 3384/4885AKR1A1 1036/4885CHRM3 2709/4885 |
| US-20230321261-A1 | AXL-SPECIFIC ANTIBODY-DRUG CONJUGATES FOR CANCER TREATMENT | AXL, BRAF, MAPK1 | CHRM1 3963/4885AKR1A1 2292/4885CHRM3 3849/4885 |
| US-20070203219-A1 | Production of dolasetron | DDOST, DAD1, DHPS | CHRM1 4275/4885AKR1A1 429/4885CHRM3 2922/4885 |
| US-20170157250-A1 | ANTIBODIES BINDING AXL | CD47, AXL, ERBB3 | CHRM1 4378/4885AKR1A1 4665/4885CHRM3 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.